Abstract

Alzheimer’s disease (AD), which is recognised as a devastating neurodegenerative disease throughout the world and lack of effective treatments, is a growing concern in modern society with a growing population of elderly patients. A growing number of studies reveal that abnormal accumulation and deposition of Aβ is responsible for AD. Inspired by this, strategies for the treatment of AD targeting-Aβ clearance have been discussed for a long period, exploring new drugs which is capable of destroying soluble Aβ oligomers and unsolvable Aβ aggregates. In this paper, results of recent clinical trials on several anti-amyloid-β drugs are presented and several emerging anti-amyloid AD therapies based on recent studies are reviewed. Furthermore, some of the current challenges and novel strategies to prevent AD are addressed. Herein, this review focuses on current pharmacotherapy of AD targeting-Aβ and intends to design a promising therapeutic agent for AD treatment.

摘要

阿尔茨海默病 (AD) 在全世界被公认为是一种毁灭性的神经退行性疾病，缺乏有效的治疗方法，随着老年患者数量的增加，在现代社会中日益受到关注。越来越多的研究表明，Aβ 的异常积累和沉积是导致 AD 的原因。受此启发，治疗AD靶向-Aβ清除的策略已经讨论了很长时间，探索能够破坏可溶性Aβ寡聚体和不可溶性Aβ聚集体的新药。本文介绍了几种抗淀粉样蛋白-β 药物的近期临床试验结果，并回顾了基于近期研究的几种新兴抗淀粉样蛋白 AD 疗法。此外，还解决了当前的一些挑战和预防 AD 的新策略。在此处，